BIOCHEMICAL, BEHAVIORAL, AND CLINICAL-STUDIES OF THE ROLE OF INOSITOL IN LITHIUM TREATMENT AND DEPRESSION

被引:92
作者
KOFMAN, O [1 ]
BELMAKER, RH [1 ]
机构
[1] MINIST HLTH,FAC HLTH SCI,CTR MENT HLTH,BEER SHEVA,ISRAEL
关键词
LITHIUM; MYOINOSITOL; L-CHIRO-INOSITOL; BIPOLAR AFFECTIVE DISORDER; LITHIUM PILOCARPINE SEIZURES; POLYURIA POLYDIPSIA;
D O I
10.1016/0006-3223(93)90052-F
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Lithium (Li) reduces brain inositol levels by inhibiting the enzyme inositol monophosphatase. The enzyme inositol-1-phosphatase was measured in human red blood cells of controls, Li-free bipolar patients, and Li-treated bipolar patients and was found to be reduced by 80% in Li-treated bipolars, thus supporting the concept that chronic Li at therapeutic concentrations inhibits this enzyme. Two behaviors in rats caused by Li, reduction of rearing, and Li-pilocarpine seizures, are reversed by intracerebroventricular replenishment of inositol. The reversal is stereospecific to the naturally occurring myo-inositol; whereas the stereoisomer L-chiro-inositol is ineffective. The reversal is dose-dependent, requiring a dose consistent with known quantities of brain inositol depletion; and is time-dependent, as inositol must be given 1-8 h before stimulation. High-dose peripheral inositol also reverses the limbic seizures induced by Li-pilocarpine, and using gas chromatography was shown to increase brain inositol levels that had been reduced by Li treatment. Low-dose inositol could be shown to reverse a peripheral Li-induced side effect, polyurialpolydipsia, in rats and in patients treated with Li. A higher dose of inositol markedly reduced Hamilton Depression Ratings in 9 of 11 unipolar major depressive disorder patients previously unresponsive to tricyclics, in an open design, but had no effect on chronic schizophrenics in a controlled double-blind randomized crossover trial. A new inositol monophosphatase inhibitor, a fungal product originally discovered as a complement inhibitor, was found to act like Li and lower the seizure threshold for subconvulsant doses of pilocarpine. These data suggest that inositol monophosphatase inhibition is a key mechanism of Li's therapeutic action and that design of new inositol monophosphatase inhibitors may be a practical strategy to create new compounds with Li-like therapeutic effects.
引用
收藏
页码:839 / 852
页数:14
相关论文
共 86 条
  • [1] REDUCED BRAIN INOSITOL IN LITHIUM-TREATED RATS
    ALLISON, JH
    STEWART, MA
    [J]. NATURE-NEW BIOLOGY, 1971, 233 (43): : 267 - &
  • [2] HIGH-DOSE DIETARY MYOINOSITOL SUPPLEMENTATION DOES NOT ALTER THE ISCHEMIA PHENOMENON IN HUMAN DIABETICS
    ARENDRUP, K
    GREGERSEN, G
    HAWLEY, J
    HAWTHORNE, JN
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 (02): : 99 - 102
  • [3] ATACK JR, 1993, J NEUROCHEM
  • [4] MAGNESIUM REVERSAL OF LITHIUM INHIBITION OF BETA-ADRENERGIC AND MUSCARINIC RECEPTOR COUPLING TO G-PROTEINS
    AVISSAR, S
    MURPHY, DL
    SCHREIBER, G
    [J]. BIOCHEMICAL PHARMACOLOGY, 1991, 41 (02) : 171 - 175
  • [5] LITHIUM INHIBITS ADRENERGIC AND CHOLINERGIC INCREASES IN GTP BINDING IN RAT CORTEX
    AVISSAR, S
    SCHREIBER, G
    DANON, A
    BELMAKER, RH
    [J]. NATURE, 1988, 331 (6155) : 440 - 442
  • [6] BARABAN JM, 1989, AM J PSYCHIAT, V146, P1251
  • [7] MYOINOSITOL TURNOVER IN THE INTACT RAT-BRAIN - INCREASED PRODUCTION AFTER D-AMPHETAMINE
    BARKAI, AI
    [J]. JOURNAL OF NEUROCHEMISTRY, 1981, 36 (04) : 1485 - 1491
  • [8] BARKAI IA, 1978, BIOL PSYCHIAT, V13, P65
  • [9] BELMAKER R H, 1990, Pharmacology and Toxicology Supplement, V66, P76
  • [10] LITHIUM RESEARCH - STATE-OF-THE-ART
    BELMAKER, RH
    KOFMAN, O
    [J]. BIOLOGICAL PSYCHIATRY, 1990, 27 (12) : 1279 - 1281